For Immediate Release

JOLT HEALTH INC. ANNOUNCES APPOINTMENT TO THE BOARD

VANCOUVER, BC, CANADA (January 15, 2026) – Jolt Health Inc. (“JOLT” and or “the Company”) (CSE:JOLT) (FSE: G1Q0) announces the appointment of Chris Farnworth to its Board of Directors as an independent director.

Chris Farnworth brings extensive expertise in business development and corporate finance to the board, with a strong focus on the global mining and energy-transition sectors. He previously served as Vice President of Business Development at a Top 50 TSX Venture Exchange company, where he played a pivotal role in securing initial project financing, leading asset acquisitions, and advancing project development initiatives.

A notable highlight of his career includes structuring and executing a successful joint venture with a private equity firm, resulting in significant operational consolidation and value creation. Mr. Farnworth also held the role of Vice President of Business Development at Noram Lithium, where he was instrumental in advancing the Clayton Valley lithium clay project, one of the most prominent lithium assets in the United States.

Currently, Mr. Farnworth is the Founder and Chief Executive Officer of Zero Carbon Technologies, a UK-based clean-technology company specializing in battery and e-waste recycling, with active operations in Spain and an expanding international footprint. His deep industry knowledge, combined with a robust global network across mining, recycling, and capital markets, underpins his commitment to identifying and executing international opportunities within the rapidly evolving green energy and circular-economy sectors.

Concurrent with the above appointment, Douglas Taylor has resigned as a member of the Company’s Board of Directors. The Company thanks Mr. Taylor for his contributions and wishes him well in future endeavors.

About Jolt Health Inc.

Jolt Health Inc. (CSE – JOLT) is a leading life sciences company focused on healthcare, biotechnology and artificial intelligence. The company currently holds exclusive licenses for innovative therapeutic and pharmaceutical products throughout Europe, the UK, and North America. The company is committed to transforming the industry through research, collaboration, and technological advancement, sharping the future of healthcare worldwide.

For further information, please contact:

Gerald Tritt, CEO
Investor Relations
Telephone: 1 (604) 343-2977
E-mail: info@jolt-health.com
www.jolt-health.com

Neither the Canadian Securities Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward Looking Statements

Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. All statements other than statements of historical fact are forward-looking statements, including, without limitation, statements regarding future financial position, business strategy, use of proceeds, corporate vision, proposed acquisitions, partnerships, joint-ventures and strategic alliances and co-operations, budgets, cost and plans and objectives of or involving the Company. Such forward-looking information reflects management's current beliefs and is based on information currently available to management. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "forecasts", "predicts", "intends", "targets", "aims", "anticipates", "may" or "believes" or variations (including negative variations) of such words and phrases or may be identified by statements to the effect that certain actions "may", "could", "should", "would", "might" or "will" be taken, occur or be achieved. A number of known and unknown risks, uncertainties and other factors may cause the actual results or performance to materially differ from any future results or performance expressed or implied by the forward-looking information. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Company including, but not limited to, the impact of general economic conditions, industry conditions, risks relating to epidemics or pandemics such as COVID–19, including the impact of COVID–19 on the Company's business, financial condition and results of operations, lack of investor demand for Bitcoin and/or Bitcoin futures exchange traded funds, and dependence upon regulatory approvals. Readers are cautioned that the assumptions used in the preparation of such information, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company does not assume any obligation to update or revise its forward-looking statements, whether as a result of new information, future events, or otherwise, except as required by securities laws.